Verax Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 10-12-2024
- Paid Up Capital ₹ 0.98 M
as on 10-12-2024
- Company Age 15 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 42.36%
(FY 2022)
- Profit -95.48%
(FY 2022)
- Ebitda -50.37%
(FY 2022)
- Net Worth 0.86%
(FY 2022)
- Total Assets 27.73%
(FY 2022)
About Verax Lifesciences
The Corporate was formerly known as Trimurti Vegoils Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.98 M, as per Ministry of Corporate Affairs (MCA) records.
Natarajan Kumaran, Devarajan Nivetha, and Kuppusamy Ramadas serve as directors at the Company.
- CIN/LLPIN
U36102HP2009PTC031136
- Company No.
031136
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jul 2009
- Date of AGM
26 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Verax Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Natarajan Kumaran  | Director | 16-May-2016 | Current |
| Devarajan Nivetha | Director | 26-Aug-2022 | Current |
Kuppusamy Ramadas  | Director | 19-Aug-2022 | Current |
Financial Performance of Verax Lifesciences.
Verax Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 42.36% increase. The company also saw a substantial fall in profitability, with a 95.48% decrease in profit. The company's net worth moved up by a moderate rise of 0.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Verax Lifesciences?
Unlock access to Verax Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Middle Mist Pharmaceuticals Private LimitedActive 9 years 4 months
Kuppusamy Ramadas is a mutual person
- Dr. Norman Laboratories Private LimitedActive 13 years 2 months
Kuppusamy Ramadas is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Verax Lifesciences?
Verax Lifesciences has a workforce of 14 employees as of Sep 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Verax Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Verax Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
